AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21733166 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews of clinicians
Number of subjects: 0
Study 19784374 — intervention group
Group type: COMPARATOR
Intervention: SP+AQ
Number of subjects: 1893
Study 19784374 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+PQ
Number of subjects: 1893
Study 19784374 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+PQ
Number of subjects: 1893
Study 19784374 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine combinations
Number of subjects: 1893
Study 17113894 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS‐1
Number of subjects: 55
Study 17113894 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS‐2
Number of subjects: 55
Study 15311654 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity
Number of subjects: 0
Study 15311654 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual responses
Number of subjects: 0
Study 15311654 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic responses
Number of subjects: 0
Study 15311654 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous saccades
Number of subjects: 0
Study 11104595 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preoperative and postoperative tube-feeding (group II)
Number of subjects: 49
Study 11104595 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-supplemented preoperative and postoperative tube-feeding (group III)
Number of subjects: 49
Study 11104595 — intervention group
Group type: COMPARATOR
Intervention: No preoperative and standard postoperative tube-feeding (group I)
Number of subjects: 49
Study 9301462 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m2) before cyclophosphamide (1500 mg/m2) for two cycles
Number of subjects: 40
Study 9301462 — intervention group
Group type: COMPARATOR
Intervention: Amifostine/cyclophosphamide only on one cycle (patients were their own control)
Number of subjects: 40
Study 9301462 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone without amifostine protection
Number of subjects: 40
Study 8281220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie
Number of subjects: 60
Study 8281220 — intervention group
Group type: COMPARATOR
Intervention: Low-fat
Number of subjects: 60
Study 8281220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 3434998 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized aggressive treatment including wide resection, adjuvant radio- or chemotherapy and management of advanced disease
Number of subjects: 304
Study 3434998 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation followed by surgery
Number of subjects: 304
Study 3434998 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 304
Study 3434998 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cytostatic therapy in patients with colonic tumours of Dukes B and C stages
Number of subjects: 304
Study 3434998 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation followed by attempted curative surgery in primarily inoperable rectal cancer
Number of subjects: 304
Study 3434998 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemicolectomy
Number of subjects: 304
Study 29938604 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 14
Study 29938604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29938604 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 14
Study 23579581 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation (PNS) for constipation predominant patients (group 1)
Number of subjects: 13
Study 23579581 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation (PNS) for incontinence predominant patients (group 2)
Number of subjects: 13
Study 22924756 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium fluoride/triclosan/copolymer (TCN/C)
Number of subjects: 35
Study 22924756 — intervention group
Group type: EXPERIMENTAL
Intervention: stannous fluoride/sodium hexametaphosphate/zinc lactate (SnF(2)/SHMP)
Number of subjects: 35
Study 22924756 — intervention group
Group type: COMPARATOR
Intervention: sodium fluoride (NaF)
Number of subjects: 35
Study 19329546 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/74 mg BZP/TFMPP
Number of subjects: 35
Study 19329546 — intervention group
Group type: COMPARATOR
Intervention: 57.6 g (6 units) alcohol
Number of subjects: 35
Study 19329546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19329546 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 35
Study 19329546 — intervention group
Group type: EXPERIMENTAL
Intervention: BZP/TFMPP alone or with alcohol
Number of subjects: 35
Study 19329546 — intervention group
Group type: EXPERIMENTAL
Intervention: BZP/TFMPP
Number of subjects: 35
Study 18622632 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1200 mg/m(2) per day (n = 12)
Number of subjects: 24
Study 18622632 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) 4-5 mg/kg per day (n = 12)
Number of subjects: 24
Study 15882244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, amoxicillin and clarithromycin (antibiotic group)
Number of subjects: 157
Study 15882244 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole and identical antibiotic placebos (control group)
Number of subjects: 157
Study 15882244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 157
Study 15882244 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group
Number of subjects: 157
Study 15882244 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study 12970012 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (EM)
Number of subjects: 458
Study 12970012 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 458
Study 11005367 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory guidance with early literacy development and provision of books at well-child visits (WCV)
Number of subjects: 352
Study 11005367 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory guidance with early literacy development and provision of books at WCV
Number of subjects: 352
Study 11005367 — intervention group
Group type: COMPARATOR
Intervention: Anticipatory guidance without book provision at WCV
Number of subjects: 352
Study 8843174 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral fish oil (FO) at 0.15 g/kg/d for 5 days
Number of subjects: 20
Study 8843174 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO) at 1.0 g/kg/d for 5 days
Number of subjects: 20
Study 1509577 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot zone therapy (10 sessions of 1 hour each at intervals of one week)
Number of subjects: 30
Study 1509577 — intervention group
Group type: COMPARATOR
Intervention: Uniform clinical care without placebo foot zone therapy
Number of subjects: 30
Study 6373340 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (100 mg orally)
Number of subjects: 6
Study 29789243 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT and AS04-HPV16/18 co-administered
Number of subjects: 1300
Study 29789243 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT, AS04-HPV16/18 and Tdap co-administered
Number of subjects: 1300
Study 29789243 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-TT alone
Number of subjects: 1300
Study 29789243 — intervention group
Group type: COMPARATOR
Intervention: Tdap and AS04-HPV16/18 co-administered
Number of subjects: 1300
Study 26450445 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 42
Study 26450445 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept
Number of subjects: 42
Study 26450445 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab
Number of subjects: 42
Study 24833067 — intervention group
Group type: EXPERIMENTAL
Intervention: Early escape per patient choice
Number of subjects: 0
Study 24833067 — intervention group
Group type: EXPERIMENTAL
Intervention: Early escape per protocol
Number of subjects: 0
Study 24833067 — intervention group
Group type: COMPARATOR
Intervention: Traditional crossover design
Number of subjects: 0
Study 23390831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 85
Study 23390831 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation
Number of subjects: 85
Study 20212302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ask Me 3 (AM3) health communication program
Number of subjects: 834
Study 20212302 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 834
Study 18349394 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/FU/FA combination therapy
Number of subjects: 2691
Study 16105610 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin 0.5% eyedrops
Number of subjects: 69
Study 16105610 — intervention group
Group type: COMPARATOR
Intervention: ofloxacin 0.3% eyedrops
Number of subjects: 69
Study 12509599 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg daily)
Number of subjects: 21
Study 12509599 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 11498702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g every 8 or 12 hours)
Number of subjects: 45
Study 9065256 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 12
Study 9065256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight (LMW) heparins
Number of subjects: 12
Study 9065256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis (fractionated or unfractionated)
Number of subjects: 12
Study 9065256 — intervention group
Group type: COMPARATOR
Intervention: Spinal/epidural anaesthesia
Number of subjects: 12
Study 1684556 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 6881119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 15 mg/day plus cleansing enemas
Number of subjects: 4
Study 6881119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 30 mg/day plus cleansing enemas
Number of subjects: 4
Study 6881119 — intervention group
Group type: COMPARATOR
Intervention: Neomycin 6 g/day plus cleansing enemas (standard therapy)
Number of subjects: 4
Study 30672248 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment at Baihui (GV 20), Fengfu (GV 16), Shenting (GV 24), Taiyang (EX‐HN 5), Shangyintang (Extra 3), Dazhong (KI 14); EA applied at Taiyang (EX‐HN 5), Baihui (GV 20), Shenting (GV 24) with dilatational wave, 10 Hz/50 Hz frequency, 0.5 to 5.0 mA intensity, once every two days, three treatments per week for 12 weeks.
Number of subjects: 40
Study 30672248 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride tablets, once a day before sleep for 12 weeks.
Number of subjects: 40
Study 30672248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups evaluated at baseline, 12 weeks, and 24 weeks after treatment.
Number of subjects: 40
Study 28230390 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprexis (Internet treatment for depression) for 8 weeks
Number of subjects: 376
Study 28230390 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (8-week delay)
Number of subjects: 376
Study 24467878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric feeding (60% of estimated requirements)
Number of subjects: 50
Study 22385554 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary delirium e-learning course
Number of subjects: 0
Study 19179295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 1937
Study 19179295 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors evaluated (body weight, diabetes, positive immune response)
Number of subjects: 1937
Study 17937685 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic developmental care (standardized nests and incubator covers)
Number of subjects: 283
Study 17937685 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP (Newborn Individualized Developmental Care and Assessment Program)
Number of subjects: 283
Study 17937685 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 283
Study 11151439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (six sessions of individual hypnotherapy)
Number of subjects: 52
Study 11151439 — intervention group
Group type: COMPARATOR
Intervention: Audiotape (therapeutic audiotape)
Number of subjects: 52
Study 11151439 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Hypnotherapy and Audiotape)
Number of subjects: 52
Study 9190123 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Glycogen (NG)
Number of subjects: 6
Study 9190123 — intervention group
Group type: EXPERIMENTAL
Intervention: Depleted Glycogen (DG)
Number of subjects: 6
Study 1398561 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of diethylstilbestrol
Number of subjects: 1646
Study 1398561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1646
Study 2993946 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4‐9 analogue (ORG 2766), 80 mg daily during 14‐28 days
Number of subjects: 21
Study 2993946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29982627 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) system
Number of subjects: 7914
Study 29982627 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 7914
Study 29982627 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS
Number of subjects: 7914
Study 29982627 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 7914
Study 26453639 — intervention group
Group type: EXPERIMENTAL
Intervention: T&E+laser
Number of subjects: 372
Study 26453639 — intervention group
Group type: EXPERIMENTAL
Intervention: T&E
Number of subjects: 372
Study 26453639 — intervention group
Group type: COMPARATOR
Intervention: PRN (control)
Number of subjects: 372
Study 26453639 — intervention group
Group type: EXPERIMENTAL
Intervention: T&E+laser and T&E
Number of subjects: 372
Study 24101698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 29
Study 24101698 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 29
Study 22587616 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher RBP4 levels
Number of subjects: 709
Study 22587616 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP4 levels in the bottom and upper quartiles
Number of subjects: 709
Study 22587616 — intervention group
Group type: EXPERIMENTAL
Intervention: Squared RBP4 term in regression modeling
Number of subjects: 709
Study 20191360 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 2-8 mg
Number of subjects: 317
Study 20191360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 18541569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented formula (31 mg/L)
Number of subjects: 106
Study 18541569 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 106
Study 18541569 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed (reference group)
Number of subjects: 106
Study 15838899 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary sacral nerve stimulation (SNS)
Number of subjects: 13
Study 12380632 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/metformin 1.25 mg/250 mg tablets BID for HbA1c < 9%; Glyburide/metformin 2.5 mg/500 mg tablets BID for HbA1c >= 9%.
Number of subjects: 828
Study 12380632 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/metformin tablets.
Number of subjects: 828
Study 10486674 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese, hypertensive, with hyperinsulinemia
Number of subjects: 77
Study 10486674 — intervention group
Group type: COMPARATOR
Intervention: Obese, hypertensive, without hyperinsulinemia
Number of subjects: 77
Study 10486674 — intervention group
Group type: COMPARATOR
Intervention: Non-obese, hypertensive, without hyperinsulinemia
Number of subjects: 77
Study 10486674 — intervention group
Group type: COMPARATOR
Intervention: Obese, normotensive, without hyperinsulinemia
Number of subjects: 77
Study 9019702 — intervention group
Group type: EXPERIMENTAL
Intervention: Special physiotherapy and learning to avoid unaesthetic postures through appropriate muscular control
Number of subjects: 0
Study 1769141 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A: rhEPO 2000 IU in 1 ml (Cilag)
Number of subjects: 18
Study 1769141 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation B: rhEPO 2000 IU in 1 ml (Boehringer Mannheim)
Number of subjects: 18
Study 1769141 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline 1 ml (placebo)
Number of subjects: 18
Study 31272569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate use
Number of subjects: 3417
Study 31272569 — intervention group
Group type: COMPARATOR
Intervention: No nitrate use (control)
Number of subjects: 3417
Study 28081945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide (FAc) 0.2 μg/day
Number of subjects: 0
Study 28081945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide (FAc) 0.5 μg/day
Number of subjects: 0
Study 28081945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide (FAc) 0.2 μg/day and 0.5 μg/day
Number of subjects: 0
Study 28081945 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 25934661 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum α-tocopherol (αT) quartiles
Number of subjects: 4708
Study 25934661 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum γ-tocopherol (γT) quartiles
Number of subjects: 4708
Study 23463655 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 (400 IU/d)
Number of subjects: 63
Study 23463655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (10,000 IU/d)
Number of subjects: 63
Study 23463655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (40,000 IU/d)
Number of subjects: 63
Study 23463655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (all doses)
Number of subjects: 63
Study 21215636 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical training
Number of subjects: 10
Study 21215636 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 10
Study 21215636 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 10
Study 21215636 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground walking
Number of subjects: 10
Study 17969902 — intervention group
Group type: EXPERIMENTAL
Intervention: Penqiangyan Granule (PG)
Number of subjects: 60
Study 17969902 — intervention group
Group type: COMPARATOR
Intervention: Penyanjing Granule (Control)
Number of subjects: 60
Study 11889008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014
Study 11889008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 10437863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 186
Study 10437863 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo plus conventional antihypertensive therapy)
Number of subjects: 186
Study 7767512 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 400 micrograms/day for 7 months
Number of subjects: 94
Study 7767512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 2178484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% prilocaine
Number of subjects: 300
Study 2178484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% prilocaine
Number of subjects: 300
Study 2178484 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% prilocaine
Number of subjects: 300
Study 2178484 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 300
Study 6104610 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 antihistamine (chlorpheniramine)
Number of subjects: 5
Study 6104610 — intervention group
Group type: COMPARATOR
Intervention: H2 antihistamines
Number of subjects: 5
Study 31788913 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiding personal self-disclosure
Number of subjects: 348
Study 31788913 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal reassuring self-disclosure
Number of subjects: 348
Study 31788913 — intervention group
Group type: COMPARATOR
Intervention: Redirecting non-disclosure with reassuring intention
Number of subjects: 348
Study 31788913 — intervention group
Group type: COMPARATOR
Intervention: Literal responses
Number of subjects: 348
Study 30741025 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen Cao granules (10 g once daily)
Number of subjects: 92
Study 30741025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 28937980 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture composed of five Lactobacilli strains and two Bifidobacteria strains, administered once a day for 60 days
Number of subjects: 21
Study 25740863 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3044
Study 25740863 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3044
Study 23591697 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution at high noise level (>65.6 dB[A])
Number of subjects: 40
Study 23591697 — intervention group
Group type: COMPARATOR
Intervention: Traffic-related air pollution at low noise level (≤ 65.6 dB[A])
Number of subjects: 40
Study 23591697 — intervention group
Group type: EXPERIMENTAL
Intervention: Black carbon (BC) at high noise level
Number of subjects: 40
Study 23591697 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide (CO) at high noise level
Number of subjects: 40
Study 21644092 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment posterior instrumentation (Group 1)
Number of subjects: 80
Study 21644092 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-segment posterior instrumentation (Group 2)
Number of subjects: 80
Study 19590222 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Massage (VM)
Number of subjects: 60